Home » Stocks » BPTH

Bio-Path Holdings, Inc. (BPTH)

Stock Price: $4.04 USD 0.10 (2.54%)
Updated Jan 14, 2021 4:00 PM EST - Market closed
Pre-market: $4.05 +0.01 (0.25%) Jan 15, 8:48 AM
Market Cap 18.77M
Revenue (ttm) n/a
Net Income (ttm) -10.72M
Shares Out 3.69M
EPS (ttm) -3.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 14
Last Price $4.04
Previous Close $3.94
Change ($) 0.10
Change (%) 2.54%
Day's Open 3.91
Day's Range 3.91 - 4.20
Day's Volume 252,031
52-Week Range 3.07 - 7.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Trial to Evaluate Ability of BP1002, Targeting Bcl...

Seeking Alpha - 2 months ago

Bio-Path Holdings' (BPTH) CEO Peter Nielsen on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: NLSN
GlobeNewsWire - 2 months ago

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

GlobeNewsWire - 2 months ago

HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to deve...

InvestorPlace - 2 months ago

BPTH stock received a boost on Thursday after Bio-Path received a notice of allowance for a strategic patent for its candidate Prexigebersen. The post Bio-Path Holdings News: Why BPTH Stock Is...

GlobeNewsWire - 2 months ago

Growing Patent Estate Creates Value and Supports Key Combination Therapies Growing Patent Estate Creates Value and Supports Key Combination Therapies

GlobeNewsWire - 4 months ago

HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology...

Zacks Investment Research - 4 months ago

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 5 months ago

Bio-Path Holdings Inc (BPTH) CEO Peter Nielsen on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

GlobeNewsWire - 5 months ago

Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Ha...

GlobeNewsWire - 5 months ago

HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...

Seeking Alpha - 7 months ago

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: NLSN
GlobeNewsWire - 8 months ago

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

24/7 Wall Street - 9 months ago

To say the least, Bio-Path Holdings Inc. (NASDAQ: BPTH) stock has taken a beating in the past five years.

24/7 Wall Street - 10 months ago

On Friday, March 6, oncology drug development company Bio-Path Holdings Inc. (NASDAQ: BPTH) reported fiscal year 2019 results.

GlobeNewsWire - 10 months ago

HOUSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...

24/7 Wall Street - 10 months ago

What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of market capitalization?

Zacks Investment Research - 11 months ago

Tap five stocks with increasing P/E ratios to try an out-of-the-box approach.

Other stocks mentioned: DENN, HEI, NVEE, OMP
GlobeNewsWire - 1 year ago

HOUSTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to de...

Zacks Investment Research - 1 year ago

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results Combination of Prexigebersen and Decitabine Showed Encouraging Safety and Efficacy Results

GlobeNewsWire - 1 year ago

HOUSTON, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...

GlobeNewsWire - 1 year ago

HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...

GlobeNewsWire - 1 year ago

Phase 1 Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients Phase 1 Clinical Trial to Evaluat...

InvestorPlace - 1 year ago

Bio-Path (BTPH) earnings for the biotechnology company's third quarter of 2019 saw BTPH stock taking a wild ride on Friday.

Seeking Alpha - 1 year ago

Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Brings 25 Years of Experience in Business Development and Marketing Brings 25 Years of Experience in Business Development and Marketing

GlobeNewsWire - 1 year ago

HOUSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to d...

GlobeNewsWire - 1 year ago

HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to dev...

Seeking Alpha - 1 year ago

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2019 Results - Earnings Call Transcript

Investors Business Daily - 1 year ago

Bio-Path rocketed Monday after withdrawing its December offering for stocks and warrants. Bio-Path is working on a number of cancer treatments.

Market Watch - 1 year ago

Bio-Path Holdings Inc.'s stock rocketed 48% in morning trade Monday, after the biotechnology company focused on cancer treatments filed to withdraw a common stock offering.

Seeking Alpha - 1 year ago

Bio-Path Holdings (BPTH) CEO, Peter Nielsen on Q4 2018 Results - Earnings Call Transcript

24/7 Wall Street - 1 year ago

Bio-Path Holdings Inc. (NASDAQ: BPTH) shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple points during the day for volatility spikes.

Benzinga - 1 year ago

Bio-Path Holdings Inc (BPTH) shares are on a tear, advancing over 160 percent on roughly 37 times their average volume Wednesday and trading up more than 200 percent Thursday afternoon.

About BPTH

Bio-Path Holdings operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical t... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Peter H. Nielsen
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
BPTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BPTH stock is "Buy" and the 12-month stock price forecast is 10.00.

Price Target
$10.00
Analyst Consensus: Buy